EPHA2 and non-small cell lung carcinoma: EphA2 is overexpressed in more than 90% of NSCLC tissues, where it correlates with poor survival rates and drives tumor growth, metastasis, and survival through mechanisms such as S897 phosphorylation and ERK1/2 activation (13, 14).